Compare Morgan Stanley (MS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Novo Nordisk A/S — how do they compare? Morgan Stanley trades at $190.02 (market cap $294.39B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Morgan Stanley is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 92 Days and Novo Nordisk A/S for 116 Days on average.
| MS | NVO | |
|---|---|---|
Market Cap | $294.39B | $165.31B |
Volume | 5,836,423 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $228.42 | $63.98 |
52-Week Low | $151.86 | $35.29 |
Typical Hold Time | 92 Days | 116 Days |
Enterprise Value | $660.04B | $179.56B |
Dividend Yield | 2.45% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $187.41, down 1.21% on the day, with a bearish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing to $66.0 billion in 2025 and net income reaching $16.9 billion, alongside three consecutive quarterly EPS beats. Analysts maintain a bullish stance with a $229.25 consensus price target, citing growth in wealth management and AI financing.
The outlook is positive given earnings momentum and strategic growth areas, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to analyst targets if execution continues, though macroeconomic and capital markets volatility pose headwinds.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
